Monocytes expand with immune dysregulation and is associated with insulin resistance in older individuals with chronic HIV

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Shikuma, Cecilia M ^a   Chow, Dominic C ^a   Gangcuangco, Louie Mar A ^a   Zhang, Guangxiang ^a   Keating, Sheila M ^b   Norris, Philip J ^b,c   Seto, Todd B ^a,d   Parikh, Nisha ^a,d   Kallianpur, Kalpana J ^a   Nakamoto, Beau K ^a,e   Nagamine, Lorna S ^a   Ndhlovu, Lishomwa C ^a   Barbour, Jason D ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d QUEEN S MEDICAL CENTER   (United States)

^e STRAUB CLINIC AND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CD14 ANTIGEN; CD16 ANTIGEN; CD38 ANTIGEN; GELATINASE B; HLA DR ANTIGEN; INTERLEUKIN 6; MYELOPEROXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERUM AMYLOID A; SERUM AMYLOID P;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DYSREGULATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MONOCYTE; PREDICTION; RISK FACTOR;

AGE FACTORS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOPHENOTYPING; INSULIN RESISTANCE; LYMPHOCYTE COUNT; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MONOCYTES; RISK FACTORS; T-LYMPHOCYTE SUBSETS;

EID: 84896381610     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090330     Document Type: Article

References (42)

1. Gutierrez AD, Balasubramanyam A (2012) Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Endocrine 41: 1-10.
2. Boufassa F, Goujard C, Viard JP, Carlier R, Lefebvre B, et al. (2012) Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort. Antivir Ther 17: 91-100.
3. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA (2010) Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 33: 2244-2249.
4. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, et al. (2010) Nomenclature of monocytes and dendritic cells in blood. Blood 116: e74-80.
5. Jalbert E, Crawford TQ, D'Antoni ML, Keating SM, Norris PJ, et al. (2013) IL-1Beta Enriched Monocytes Mount Massive IL-6 Responses to Common Inflammatory Triggers among Chronically HIV-1 Infected Adults on Stable Anti-Retroviral Therapy at Risk for Cardiovascular Disease. PLoS One 8: e75500.
6. Barbour JD, Jalbert EC, Chow DC, Gangcuangco LM, Norris PJ, et al. (2014) Reduced CD14 expression on classical monocytes and vascular endothelial adhesion markers independently associate with carotid artery intima media thickness in chronically HIV-1 infected adults on virologically suppressive antiretroviral therapy. Atherosclerosis 232: 52-58.
7. Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964. (Pubitemid 41746764)
8. Strauss-Ayali D, Conrad SM, Mosser DM (2007) Monocyte subpopulations and their differentiation patterns during infection. J Leukoc Biol 82: 244-252. (Pubitemid 47230633)
9. Geissmann F, Jung S, Littman DR (2003) Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71-82. (Pubitemid 36859902)
10. Ziegler-Heitbrock L (2007) The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 81: 584-592.
11. Seidler S, Zimmermann HW, Bartneck M, Trautwein C, Tacke F (2010) Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. BMC Immunol 11: 30.
12. Ellery PJ, Tippett E, Chiu YL, Paukovics G, Cameron PU, et al. (2007) The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 178: 6581-6589. (Pubitemid 46717442)
13. Kusao I, Shiramizu B, Liang CY, Grove J, Agsalda M, et al. (2012) Cognitive performance related to HIV-1-infected monocytes. J Neuropsychiatry Clin Neurosci 24: 71-80.
14. Funderburg NT, Zidar DA, Shive C, Lioi A, Mudd J, et al. (2012) Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood 120: 4599-4608.
15. Han J, Wang B, Han N, Zhao Y, Song C, et al. (2009) CD14(high)CD16(+) rather than CD14(low)CD16(+) monocytes correlate with disease progression in chronic HIV-infected patients. J Acquir Immune Defic Syndr 52: 553-559.
16. Min D, Brooks B, Wong J, Salomon R, Bao W, et al. (2012) Alterations in monocyte CD16 in association with diabetes complications. Mediators Inflamm 2012: 649083.
17. Corrales JJ, Almeida M, Burgo RM, Hernandez P, Miralles JM, et al. (2007) Decreased production of inflammatory cytokines by circulating monocytes and dendritic cells in type 2 diabetic men with atherosclerotic complications. J Diabetes Complications 21: 41-49. (Pubitemid 44960839)
18. Pandzic Jaksic V, Gizdic B, Miletic Z, Trutin-Ostovic K, Jaksic O (2013) Association of monocyte CCR2 expression with obesity and insulin resistance in postmenopausal women. Clin Invest Med 36: E24-31.
19. Yang M, Gan H, Shen Q, Tang W, Du X, et al. (2012) Proinflammatory CD14+CD16+ monocytes are associated with microinflammation in patients with type 2 diabetes mellitus and diabetic nephropathy uremia. Inflammation 35: 388-396.
20. (2013) Executive summary: standards of medical care in diabetes - 2013. Diabetes Care 36 Suppl 1: S4-S10.
21. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109: 433-438. (Pubitemid 38133916)
22. Scarpellini E, Tack J (2012) Obesity and metabolic syndrome: an inflammatory condition. Dig Dis 30: 148-153.
23. Skalicky J, Muzakova V, Kandar R, Meloun M, Rousar T, et al. (2008) Evaluation of oxidative stress and inflammation in obese adults with metabolic syndrome. Clin Chem Lab Med 46: 4992505.
24. Fernandez-Real JM, Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24: 2782301.
25. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5: e203.
26. Sandler NG, Wand H, Roque A, Law M, Nason MC, et al. (2011) Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 203: 780-790.
27. Deeks SG, Phillips AN (2009) HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 338: a3172.
28. Deeks SG (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62: 141-155.
29. Jalbert E CT, D'Antoni ML, Keating SM, Norris PJ, Nakamoto BK, et al. (2013) IL-1b Enriched Monocytes Mount Massive IL-6 Responses to Common Inflammatory Triggers among Chronically HIV-1 Infected Adults on Stable Anti-Retroviral Therapy at Risk for Cardiovascular Disease. PLoS ONE in press.
30. Hulgan T, Raffanti S, Kheshti A, Blackwell RB, Rebeiro PF, et al. (2005) CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J Infect Dis 192: 950-957. (Pubitemid 41266790)
31. Hulgan T, Shepherd BE, Raffanti SP, Fusco JS, Beckerman R, et al. (2007) Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis 195: 425-431. (Pubitemid 46146121)
32. Moore DM, Hogg RS, Yip B, Craib K, Wood E, et al. (2006) CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL. HIV Med 7: 383-388. (Pubitemid 44123249)
33. Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, et al. (2012) HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis 55: 126-136.
34. El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, et al. (2005) Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 6: 114-121. (Pubitemid 40425975)
35. Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, et al. (2012) Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Int AIDS Soc 15: 17426.
36. Limone P, Biglino A, Valle M, Degioanni M, Paola Servato M, et al. (2003) Insulin resistance in HIV-infected patients: relationship with pro-inflammatory cytokines released by peripheral leukocytes. J Infect 47: 52-58. (Pubitemid 36850136)
37. Hamsten A, Wiman B, de Faire U, Blomback M (1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313: 1557-1563. (Pubitemid 16177394)
38. Erzen B, Sabovic M (2013) In young post-myocardial infarction male patients elevated plasminogen activator inhibitor-1 correlates with insulin resistance and endothelial dysfunction. Heart Vessels 28: 570-577.
39. Guzman-Fulgencio M, Medrano J, Rallon N, Echeverria-Urabayen A, Miguel Benito J, et al. (2011) Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. J Infect 63: 382-390.
40. De Larranaga G, Galich A, Puga L, Alonso B, Benetucci J (2004) Insulin resistance status is an important determinant of PAI-1 levels in HIV-infected patients, independently of the lipid profile. J Thromb Haemost 2: 532-534. (Pubitemid 40185672)
41. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E (2002) Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 29: 441-449. (Pubitemid 34456334)
42. van Vonderen MG, Hassink EA, van Agtmael MA, Stehouwer CD, Danner SA, et al. (2009) Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J Infect Dis 199: 1186-1194.